Adial Pharmaceuticals Announces CMO’s Departure and Leadership Changes
Company Announcements

Adial Pharmaceuticals Announces CMO’s Departure and Leadership Changes

Adial Pharmaceuticals Inc (ADIL) has issued an update.

Adial Pharmaceuticals, Inc. has announced the termination of its consulting agreement with Dr. Bankole A. Johnson, which will result in his departure from the role of Chief Medical Officer effective May 17, 2024. The agreement, in place since March 2019 and amended twice in 2022, marks a significant change in the company’s leadership structure.

For detailed information about ADIL stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAdial receives notice of allowance for U.S. patent related to AD04
TheFlyAdial Pharmaceuticals commends NIAAA’s new definition of recovery
TheFlyAdial Pharmaceuticals announces database lock in PK study of AD04
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App